Insider · CIK 0001706399
Erez Chimovits
Files at ADRX (ADARx Pharmaceuticals, Inc.), UPB (Upstream Bio, Inc.). First filing Oct 17, 2024, latest Sep 30, 2026.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
ADRX: ADARx Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
UPB: Upstream Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | ADARx Pharmaceuticals, Inc. | $1.0M 61,516 shares | +1% | - | |
| 65Notable | Upstream Bio, Inc. | $14M 825,000 shares | +85% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +7,127,019 | - | - | 7,127,019 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +1,333,975 | - | - | 8,460,994 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +513,067 | - | - | 8,974,061 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Common Stockindirect: See footnotes | +256,448 | - | - | 9,230,509 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +61,516 | $17.00 | $1.0M | 9,292,025 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -7,127,019 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,333,975 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See footnotes | -513,067 | $0.00 | $0 | 0 | 12 d ago |
| Sep 28, 2026 | ADRX ADARx Pharmaceuticals, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -256,448 | $0.00 | $0 | 0 | 12 d ago |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Common Stockindirect: See Footnote | +721,956 | - | - | 973,716 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +165,000 | $17.00 | $2.8M | 1,138,716 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Common Stockindirect: See Footnote | +2,887,833 | - | - | 3,894,873 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +660,000 | $17.00 | $11M | 4,554,873 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -524,500 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -2,098,000 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -197,456 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | UPB Upstream Bio, Inc. | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -789,833 | - | - | 0 | Oct 17, 2024 |
| Oct 10, 2024 | UPB Upstream Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,096 | $0.00 | $0 | 17,096 | Oct 15, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.